stroke risk between 2 antiplatelet treatment arms. It is difficult to conceive how a patient who is deemed warfarin ineligible can be randomized to another effective anticoagulant unless obvious differences exist such as route of administration or elimination or proven advantages of the drug to be tested. We therefore believe that the known lack of efficacy of aspirin in high-risk patients and the subjectivity of the definition of warfarin ineligibility raise concerns about the trial that Connolly and colleagues propose.
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